Technical Analysis for BNTC - Benitec Biopharma Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
1.69 | -1.74% | -0.03 |
BNTC closed down 1.74 percent on Friday, May 24, 2019, on 1.77 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 30
*** please verify all earnings dates ***| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical BNTC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -1.74% | |
| BB Squeeze Ended | Range Expansion | -1.74% | |
| 180 Bearish Setup | Bearish Swing Setup | -1.74% | |
| Bollinger Band Squeeze | Range Contraction | -1.74% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2019
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Biotechnology Biopharmaceutical Biology Pain Chemotherapy Genetics Gene Expression Genetic Engineering HIV/Aids Wet Age Related Macular Degeneration Hepatitis B Hepatitis C Huntington's Disease Retinitis Pigmentosa RNA Clinical Applications Oculopharyngeal Muscular Dystrophy Chronic And Life Threatening Conditions
Biotechnology Biopharmaceutical Biology Pain Chemotherapy Genetics Gene Expression Genetic Engineering HIV/Aids Wet Age Related Macular Degeneration Hepatitis B Hepatitis C Huntington's Disease Retinitis Pigmentosa RNA Clinical Applications Oculopharyngeal Muscular Dystrophy Chronic And Life Threatening Conditions
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BNTC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 4.9 |
| 52 Week Low | 1.01 |
| Average Volume | 5,835 |
| 200-Day Moving Average | 2.1059 |
| 50-Day Moving Average | 1.8923 |
| 20-Day Moving Average | 1.8751 |
| 10-Day Moving Average | 1.8247 |
| Average True Range | 0.1161 |
| ADX | 16.35 |
| +DI | 18.835 |
| -DI | 29.0068 |
| Chandelier Exit (Long, 3 ATRs ) | 1.6816 |
| Chandelier Exit (Short, 3 ATRs ) | 1.9283 |
| Upper Bollinger Band | 2.055 |
| Lower Bollinger Band | 1.6952 |
| Percent B (%b) | -0.01 |
| BandWidth | 19.18831 |
| MACD Line | -0.0423 |
| MACD Signal Line | -0.0177 |
| MACD Histogram | -0.0247 |
| Fundamentals | Value |
|---|---|
| Market Cap | 17.33 Million |
| Num Shares | 10.3 Million |
| EPS | -0.52 |
| Price-to-Earnings (P/E) Ratio | -3.25 |
| Price-to-Sales | 3.15 |
| Price-to-Book | 1.63 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.75 | ||||
| Resistance 3 (R3) | 1.76 | 1.74 | 1.74 | ||
| Resistance 2 (R2) | 1.74 | 1.73 | 1.74 | 1.74 | |
| Resistance 1 (R1) | 1.72 | 1.72 | 1.71 | 1.71 | 1.73 |
| Pivot Point | 1.70 | 1.70 | 1.70 | 1.70 | 1.70 |
| Support 1 (S1) | 1.68 | 1.69 | 1.67 | 1.67 | 1.65 |
| Support 2 (S2) | 1.66 | 1.68 | 1.66 | 1.64 | |
| Support 3 (S3) | 1.64 | 1.66 | 1.64 | ||
| Support 4 (S4) | 1.63 |
